Navigation Links
Lucintel Profiles Leaders in Generic Drugs Industry: Global Market Expected to Reach US $335.8 Billion in 2017
Date:5/14/2013

Irving, TX (PRWEB) May 14, 2013

Top companies are making strategic acquisitions to expand their global footprint, together with taking advantage of established business and expertise gained through the acquired company. The global generic drugs industry experienced average growth over the last five years and is expected to reach approximately US $335.8 billion in 2017.

Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the global generic drugs companies and presents its findings in “Top Five Global Generic Drug Companies Performance, Strategies, and Competitive Analysis.” The report provides detailed insight into the performance of the top five generic drug companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.

The fragmented generic drugs industry includes producers of medications whose patent or marketing rights have expired. The industry includes drugs from all therapeutic areas: central nervous system, cardiovascular drugs, oncology drugs, and others. A combination of factors such as technology innovations, patent expiration, aging population, and changing lifestyles substantially affect market dynamics. In this study, Lucintel profiles the following five companies with detailed competitive assessments:

  •     Abbott Laboratories             
  •     Mylan Inc.                                                
  •     Novartis AG                        
  •     Teva Pharmaceuticals Ind. Ltd.    
  •     Watson Pharmaceuticals Inc        

As indicated in Lucintel’s study, the Asia Pacific (APAC) region holds good growth potential. India is expected to play an increasing role in the global economy as demand from a growing population continues to drive consumption for generic drugs. Major pharmaceuticals companies are planning to invest in the Asian markets to gain the market share for generic drugs.

This medical market report provides industry leaders with a competitive benchmarking of the world’s top five generic drug companies. The study provides up-to-date information on the market share, profit margins, capabilities, and business strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis, and insight, critical to the development and implementation of effective marketing and sales plans.

For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk(at)lucintel(dot)com. Lucintel provides cutting-edge decision support services that facilitate critical decisions with greater speed, insight, M & A due diligence and cost efficiency. To learn more, visit http://www.lucintel.com

Read the full story at http://www.prweb.com/releases/2013/5/prweb10730655.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lucintel Estimates Global Home Healthcare Device Industry Reach US $29 Billion in 2017
2. Lucintel Report Outlines $100 Billion Market for Global Oncology Drugs Industry in 2018
3. CodingCertification.Org in the Top 5 Percent in LinkedIn Most Viewed Profiles in 2012
4. Global cardiology leaders meet in Dubai
5. Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology
6. Leaders in childrens health to gather in Boston
7. Chinese Drywall Complaint Center Now Demands Leadership From Obama & EPA, For Homeowners In Florida And In The US Southeast Stuck In Toxic Chinese Drywall Hell-Forward?
8. UCLA School of Dentistry gets $5M from NIH to train future leaders in oral health research
9. A breath of fresh air: Childhood Asthma Leadership Coalition launches
10. College biology faculty named Leadership Fellows
11. UC Riverside Biologist named a Leadership Fellow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... Pink , a national non-profit organization focusing on the prevention and early detection of breast ... proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder Lindsay ... the Board and launched a national search to find a visionary new leader to grow ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP ... food supplements, announced its popular products are now available for purchase on StackedNutrition.com, ... prioritizes the use of premium natural ingredients in making all of its products. ...
(Date:4/24/2017)... NEW PORT RICHEY, Fla. (PRWEB) , ... April ... ... Disease Control and Prevention (CDC), rising prescription opioid overdose deaths now claim the ... (DEA) has slashed its civil case filings against drug manufacturers, distributors, pharmacies and ...
(Date:4/24/2017)... ... 2017 , ... As a former supermodel known for her timeless beauty, Joan ... single women is that she put all the words in her new book, "Manifest ... personal experiences and sparkling sense of humor have inspired her to write a book ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
Breaking Medicine Technology: